CHICAGO—Bradley A. Keywell, a significant shareholder of Tempus AI, Inc. (NASDAQ:TEM), has sold shares worth approximately $33.1 million, according to a recent SEC filing. The transactions involved the sale of Class A Common Stock over three days, from January 15 to January 17, 2025. The company, currently valued at $5.5 billion, has shown strong revenue growth of 32% over the last twelve months, according to InvestingPro data.
The stock sales were conducted at prices ranging from $34.82 to $36.04 per share. Following these transactions, Keywell now holds 15,218,365 shares indirectly through BK TL21 LLC. InvestingPro analysis suggests the stock may be undervalued at current levels, with additional insights available to subscribers.
Tempus AI, headquartered in Chicago, is known for its work in computer programming and data processing services. The company maintains a healthy liquidity position with a current ratio of 2.69 and operates with moderate debt levels. InvestingPro subscribers can access 5 additional key insights about Tempus AI's financial health and growth prospects.
In other recent news, Tempus AI Inc. has been the focus of several significant developments. The company announced preliminary fourth-quarter 2024 total revenues of approximately $200 million, reflecting a 35% growth, and adjusted the full-year 2024 revenue guidance to $693 million. Despite falling short of expectations, Loop Capital maintained a Buy rating on Tempus AI, albeit with a reduced target price.
Furthermore, Tempus AI revealed the development of a whole-genome sequencing test, xH, for hematological cancer patients, currently available for research purposes. The company also reported a 30% annual revenue growth in 2024, with a total revenue of approximately $693 million.
Several financial firms have adjusted their outlook on Tempus AI. Piper Sandler raised the price target from $40 to $70, maintaining a neutral rating. Stifel downgraded the stock from Buy to Hold but increased the price target to $65, while Needham raised its stock price target to $56 and maintained a Buy rating.
Additionally, Tempus AI is in the process of acquiring genetics firm Ambry, a move that is expected to introduce immediate genomics capabilities and promising significant opportunities in data and applications over time. The company's recent FDA clearance of its Tempus ECG-AF device, an AI tool for identifying patients at higher risk of atrial fibrillation/flutter, and a strategic partnership with Avacta Therapeutics were other significant developments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.